6-52017596-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_138694.4(PKHD1):āc.5414A>Gā(p.Glu1805Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000083 in 1,613,764 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E1805V) has been classified as Uncertain significance.
Frequency
Consequence
NM_138694.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PKHD1 | NM_138694.4 | c.5414A>G | p.Glu1805Gly | missense_variant | 34/67 | ENST00000371117.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PKHD1 | ENST00000371117.8 | c.5414A>G | p.Glu1805Gly | missense_variant | 34/67 | 1 | NM_138694.4 | P2 | |
PKHD1 | ENST00000340994.4 | c.5414A>G | p.Glu1805Gly | missense_variant | 34/61 | 5 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152166Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000439 AC: 11AN: 250754Hom.: 0 AF XY: 0.0000369 AC XY: 5AN XY: 135542
GnomAD4 exome AF: 0.0000883 AC: 129AN: 1461598Hom.: 0 Cov.: 32 AF XY: 0.0000880 AC XY: 64AN XY: 727094
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152166Hom.: 0 Cov.: 33 AF XY: 0.0000404 AC XY: 3AN XY: 74338
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 09, 2014 | The c.5414A>G (p.E1805G) alteration is located in exon 34 (coding exon 33) of the PKHD1 gene. This alteration results from a A to G substitution at nucleotide position 5414, causing the glutamic acid (E) at amino acid position 1805 to be replaced by a glycine (G). The heterozygous missense change is ultra rare in healthy individuals:_x000D_ Based on data from the NHLBI Exome Sequencing Project (ESP), the PKHD1 c.5414A>G alteration was observed in 1 among 13006 total alleles studied (0.01%). Allele frequency data for this nucleotide position are not currently available from the 1000 Genomes Project. Based on data from the Genome Aggregation Database (gnomAD), the c.5414A>G alteration was observed among 0.004% (10/276,556) of total alleles studied, having been observed in 0.02% (1/6456) Other ethnicity alleles, 0.006% (7/126,174) Non-Finnish European alleles, and 1 allele in 23,972 African alleles and 34,400 Latino alleles each. Though some variants may appear to be rare due to database-specific ethnic underrepresentation, rare missense alleles commonly exhibit a deleterious effect on protein function (Kryukov, 2007; Tennessen, 2012). A nearby amino acid change has been observed in affected individuals: _x000D_ A missense change in the nearby amino acid (R1804C), in combination with a second splice alteration, was reported in a French patient with a fetal presentation of ARPKD (Sharp, 2005). The altered amino acid is not conserved throughout evolution:_x000D_ The p.E1805 amino acid is not well conserved in available vertebrate species. The alteration is predicted benign by in silico models:_x000D_ The p.E1805G alteration is predicted to be benign by Polyphen and tolerated by SIFT in silico analyses. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Autosomal recessive polycystic kidney disease Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Nov 17, 2022 | BP4 - |
Polycystic kidney disease 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 01, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at